Teresa Gentile, MD, PhD

MM1OA-EA02 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Read more

MM1YA-S01 - A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
Read more

myeloMATCH - Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Read more

SNDX-5613-0708 - A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
Read more

Allogeneic Peripheral Blood Stem Cell Transplant Utilizing Non-Myeloablative Conditioning Therapy. A Phase II Study.
Read more

Allogeneic Hematopoietic Stem Cell Transplatation for CLL, CML, AML, ALL, Myelodysplasia and Non-Hodgkin's Lymphoma after Total Body Irradiation and Cyclophosphamide Conditioning or Cyclophosphamide and ATG Conditioning For Aplastic Anemia.
Read more